CAGR of over 11% forecast for atopic dermatitis market

New research predicts that the atopic dermatitis market will grow from $6.4 billion in 2017 to $18.3 billion in 2027 across the seven major markets (7MM = USA, France, Germany, Italy, Spain, the UK, and Japan), expanding at a compound annual growth rate (CAGR) of 11.1%.

Data and analytics company GlobalData’slatest report: ‘ Atopic Dermatitis: Global Drug Forecast and Market Analysis to 2027’ states that a drive to address the high level of unmet needs fuels strong growth in the market, with widening appreciation that atopic dermatitis is a highly variable disease and that not every patient will react in the same way to the same therapy.

Antoine Grey, pharma analyst at Global Data, says: “Developers operating in the dermatology space are aware of the enormous patient potential of the atopic dermatitis market; however, the challenge lies with the fact that first-line therapy is dominated by cheap, genericized topical drugs such as corticosteroids and TCIs. These have created a considerable barrier for any new drug hoping to penetrate the mild-to-moderate patient segment, and an additional obstacle for any developer looking to gain a meaningful return on investment for a novel therapy.